Exploiting Genomic Instability in Cancer: DNA Damage and Immuno Oncology

New England Structural Biology Association (NESBA) presents a one day conference on Exploiting Genomic Instability in Cancer: DNA Damage and Immuno Oncology.

Immunotherapies, including checkpoint inhibitors and adoptive transfer therapies, are revolutionizing cancer treatment. Neoantigens arising as a result of high mutational rates seem to drive the efficacy of immunotherapies, enhancing T cell reactivity against tumor cells. This is leading to increasing evidence of a positive correlation between mutational burden and clinical outcome of immunotherapies. During this meeting we will investigate the implications of genomic instability as a driver of the efficacy of immunotherapies, covering important aspects such as the exploration of genomic instability to enhance the clinical activity of immunotherapies.

LaCava Center
Bentley University
Waltham, MA
Thursday, June 30, 2016
8:00 am - 6:00 pm


8:00-8:50 AM  Registration and light breakfast 
8:50-9:00 AM  Opening remarks: Vanessa Almendro/Boris Engels
Session 1:
 Immune system-centric mechanisms in IO: additional considerations
Boris Engels (Novartis Institutes for BioMedical Research)
9:00-10:00  Keynote: Glenn Dranoff, (Novartis Institutes for BioMedical Research)
"Mechanism of protective tumor immunity"
10:00-10:45  Matthew Goldstein, (Neon Therapeutics)
Neoantigen Vaccine Combinations"
10:45-11:00  Tea Break
11:00-11:45  Shadmehr (Shawn) Demehri, (Massachusetts General Hospital)
Immune Regulation of Early Carcinogenesis
11:45-12:30  Mark Cobbold, (Massachusetts General Hospital)
Role of phosphopeptides in immune recognition of cancer cells” 
12:30-1:30  Lunch
Session 2:
  Tumor cell centric mechanisms in IO: mutational load and DNA damage
Vanessa Almendro (Vertex Pharmaceuticals)
1:30-2:15 Ana C Anderson, (Brigham and Women’s Hospital)
Distinct biological roles of checkpoint receptors” 
2:15-3:00  Christina Pfirschke, (Massachusetts General Hospital)
Strategies to enhance patient responses to checkpoint inhibitors” 
3:00-3:15  Tea break
3:15-4:00  Kenzie McIsaac, (Novartis Institutes for BioMedical Research)
"DNA-damage, mutation burden and the tumor microenvironment: what can we learn from genomics data?"
4:00-4:30  Lori Taylor, (Vertex Pharmaceuticals)
"The Impact of IO on the Future Oncology Landscape"
4:30-6:00  Mixer / Networking session

Meeting Organizers

Maps, Directions & Lodging Information

Our full-day event will take place at Bentley University. Please click here to find directions and detailed information on area lodging.

 Back to top